Stock Events

Stock Events

Elevation Oncology 

$0.37
22
-$0.01-2.12% Tuesday 20:00

Statistics

Day High
0.37
Day Low
0.37
52W High
0.98
52W Low
0.22
Volume
4,383,421
Avg. Volume
1,268,362
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

6AugExpected
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
-0.26
-0.17
-0.08
0
Expected EPS
-0.214071
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-44.49MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ELEV. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
Utilizes CRISPR technology for cancer gene editing, directly competing with Elevation Oncology's gene-focused therapies.
Novartis
NVS
Mkt Cap237.61B
Large pharma with a strong oncology pipeline, including targeted therapies that compete with Elevation Oncology's niche.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Offers a broad range of cancer treatments, including targeted therapies that rival Elevation Oncology's approach.
Merck
MRK
Mkt Cap214.76B
Has a significant presence in oncology, with products that compete in the same space as Elevation Oncology's treatments.
AMGEN
AMGN
Mkt Cap160.66B
Develops targeted therapies and precision medicine in oncology, competing with Elevation Oncology's strategy.
Gilead Sciences
GILD
Mkt Cap148.78B
Active in oncology with a focus on innovative treatments, posing competition to Elevation Oncology's targeted therapies.
Pfizer
PFE
Mkt Cap140.15B
Its oncology division includes targeted therapies that compete with Elevation Oncology's cancer treatment approach.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Engages in precision oncology, directly competing with Elevation Oncology's focus on specific cancer mutations.

About

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Show more...
CEO
Ms. Tammy Furlong CPA, P.M.P.
Employees
34
Country
US
ISIN
US28623U1016

Listings

0 Comments

Share your thoughts

FAQ

What is Elevation Oncology stock price today?▼
The current price of ELEV is $0.37 USD — it has decreased by -2.12% in the past 24 hours. Watch Elevation Oncology stock price performance more closely on the chart.
What is Elevation Oncology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Elevation Oncology stocks are traded under the ticker ELEV.
Is Elevation Oncology stock price growing?▼
ELEV stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Elevation Oncology has showed a +39.31% increase.
What is Elevation Oncology revenue for the last year?▼
Elevation Oncology revenue for the last year amounts to 0 USD.
What is Elevation Oncology net income for the last year?▼
ELEV net income for the last year is -44.49M USD.
How many employees does Elevation Oncology have?▼
As of April 02, 2026, the company has 34 employees.
In which sector is Elevation Oncology located?▼
Elevation Oncology operates in the Health Care sector.
When did Elevation Oncology complete a stock split?▼
Elevation Oncology has not had any recent stock splits.
Where is Elevation Oncology headquartered?▼
Elevation Oncology is headquartered in Boston, US.